Compare · APLM vs NVO
APLM vs NVO
Side-by-side comparison of Apollomics Inc. (APLM) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both APLM and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 2807.5x APLM ($76.7M).
- NVO has been more active in the news (9 items in the past 4 weeks vs 6 for APLM).
- NVO has more recent analyst coverage (25 ratings vs 0 for APLM).
- Company
- Apollomics Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $76.7M
- $215.46B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 6
- 9
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest APLM
- Director Huang Ya-Chi converted options into 500 units of CLASS A ORDINARY SHARES, increasing direct ownership by 50% to 1,500 units (SEC Form 4)
- SEC Form D filed by Apollomics Inc.
- Chief Operating Officer Chen Yi-Kuei bought $300,000 worth of CLASS A ORDINARY SHARES (20,000 units at $15.00) (SEC Form 4)
- Chief Financial Officer Lin Peter Kuan-How bought $400,005 worth of CLASS A ORDINARY SHARES (26,667 units at $15.00), increasing direct ownership by 120% to 48,979 units (SEC Form 4)
- Chief Executive Officer Chen Hung-Wen bought $7,550,004 worth of CLASS A ORDINARY SHARES (536,667 units at $14.07), increasing direct ownership by 182% to 418,334 units (SEC Form 4)
- Apollomics Announces $10 Million Private Placement Transaction
- SEC Form 3 filed by new insider Yen Hung Hsien
- SEC Form 6-K filed by Apollomics Inc.
- SEC Form 6-K filed by Apollomics Inc.
- Apollomics Regains Full Compliance with Nasdaq Listing Requirements
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S